Panelists discuss how initiating VMAT2 inhibitors for tardive dyskinesia requires careful consideration of factors like cost, patient tolerance, organ function, and drug interactions, emphasizing gradual dosing and shared decision-making to balance symptom control with adverse effect management in a personalized treatment approach.